Interactions between β-amyloid and central cholinergic neurons: Implications for Alzheimer's disease

Journal of Psychiatry and Neuroscience

Volumn 29, Issue 6, 2004, Pages 427-441

  Kar, Satyabrata ^a,d   Slowikowski, Stephen P M ^a   Westaway, David ^b,c   Mount, Howard T J ^b,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Ctr for Res in Neurodeg Diseases   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; G PROTEIN COUPLED RECEPTOR; NICOTINIC RECEPTOR; PROTEIN KINASE C; TAU PROTEIN;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL LOSS; CELL SURVIVAL; CHOLINERGIC NERVE CELL; CHOLINERGIC TRANSMISSION; COGNITIVE DEFECT; CONTROLLED STUDY; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MOUSE; NEOCORTEX; NEUROBLASTOMA CELL; NEUROFIBRILLARY TANGLE; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; SENILE PLAQUE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; CELL DEATH; CHOLINERGIC FIBERS; HUMANS; NEUROFIBRILLARY TANGLES; NEURONS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RECEPTORS, CHOLINERGIC; TAU PROTEINS;

EID: 11344265672     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (151)

1. Whitehouse PJ. Genesis of Alzheimer's disease. Neurology 1997;48(Suppl 7):S2-7.
2. Terry RD, Katzman R. Senile dementia of the Alzheimer type. Ann Neurol 1983;14:497-506.
3. Irizarry M, Hyman B. Alzheimer's disease. In: Batchlor T, Cudkowicz M, editors. Principles of neuroepidemiology. Boston: Butterworth-Heinemann; 2001. p. 69-98.
4. Levy-Lahad E, Wasco W, Pookraj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269:973-7.
5. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375: 754-60.
6. Holmes C. Genotype and phenotype in Alzheimer's disease. Br J Psychiatry 2002;180:131-4.
7. Strittmatter WJ, Saunders AM, Schmeckel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977-81.
8. Poirier J, Davingnon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342:697-9.
9. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998;19:357-60.
10. Wang X, Luedecking EK, Minster RL, Ganguli M, DeKosky ST, Kamboh MI. Lack of association between alpha2-macroglobulin polymorphisms and Alzheimer's disease. Hum Genet 2001;108:105-8.
11. Selkoe DJ. Alzheimer's disease: genes, proteins and therapy. Physiol Rev 2001;81:741-66.
12. Muller-Spahn F, Hock C. Risk factors and differential diagnosis of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1999;249(Suppl 3):37-42.
13. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 1993;16:460-5.
14. Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 1998;21:479-505.
15. Lee VM. Disruption of the cytoskeleton in Alzheimer's disease. Curr Opin Neurobiol 1995;5:663-8.
16. Iqbal K, Alonso AC, Gong CX, Khatoon S, Pei JJ, Wang JZ, et al. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. J Neurol Transm Suppl 1998;53: 169-80.
17. Brion JP, Anderton BH, Authelet M, Dayanandan R, Leroy K, Lovestone S, et al. Neurofibrillary tangles and tau phosphorylation. Biochem Soc Symp 2001;67:81-8.
18. Billingsley ML, Kincaid RL. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneraion. Biochem 1997;323:577-91.
19. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42: 631-9.
20. Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol 1995;52:81-8.
21. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997;56:321-39.
22. Clippingdale AB, Wade JD, Barrow CJ. The amyloid-β peptide and its role in Alzheimer's disease. J Pept Sci 2001;7:227-49.
23. Wisniewski T, Ghiso J, Frangione B. Biology of Aβ amyloid in Alzheimer's disease. Neurobiol Dis 1997;4:313-28.
24. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000;283:1571-7.
25. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46:860-6.
26. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999;155: 853-62.
27. Giaccone G, Tagliavini F, Linoli G, Bouras C, Frigerio L, Frangione B, et al. Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci Lett 1989;97:232-8.
28. Tanzi RE. Neuropathology in the Down's syndrome brain. Nat Med 1996;2:31-2.
29. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 1993;13:1676-87.
30. Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 1996;16:921-32.
31. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 1992;359: 322-5.
32. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer β-peptide from biological fluids. Nature 1992;359:325-7.
33. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, et al. Production of Alzheimer's β protein by normal proteolytic processing. Science 1992;258:126-9.
34. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995;73:523-7.
35. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102.
36. Calhoun M, Wiederhold K, Abramowski D, Phinney AL, Sturchler-Pierrat C, Staufenbiel M, et al. Neuron loss in APP transgenic mice. Nature 1998;395:755-6.
37. Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold KH, Walker L, et al. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci 2002;22:515-22.
38. Giovannelli L, Casamenti F, Scali C, Bartolini L, Pepeu G. Differential effects of amyloid peptides β-(1-40) and β-(25-35) injections into rat nucleus basalis. Neuroscience 1995;66:781-92.
39. Harkany T, Lengyel Z, Soos K, Penke B, Luiten PG, Gulya K. Cholinotoxic effects of β-amyloid1-42 peptide on cortical projections of the rat nucleus basalis magnocellularis. Brain Res 1995;695:71-5.
40. Itoh A, Nitta A, Nadai M, Nishimura K, Hirose M, Hasegawa T, et al. Dysfunction of cholinergic and dopaminergic neuronal systems in β-amyloid protein-infused rats. J Neurochem 1996;66:1113-7.
41. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yanker BA. Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nat Med 1998;4:827-31.
42. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science 2001;293:1491-5.
43. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001;293:1487-91.
44. Braak H, Braak E. Pathology of Alzheimer's disease. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia: Saunders; 1994. p. 585-613.
45. Geula C, Mesulam MM. Cholinergic system and related neuropathological predilection patterns in Alzheimer's disease. In: Terry RD, Katzman R, Bick KL, editors. Alzheimer disease. New York: Raven Press; 1994. p. 263-91.
46. DeKosky ST, Scheff SW, Styren SD. Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration 1996;5:417-21.
47. Lander CJ, Lee JM. Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 1998;57:719-31.
48. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-47.
49. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
50. Blusztajn JK. Berse B. The cholinergic neuronal phenotype in Alzheimer's disease. Metab Brain Dis 2000;15:45-64.
51. Perry EK, Tomlinson BE, Blessed G, Bergman K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2:1457-9.
52. Bartus RT, Dean RL III, Beer B, Lipa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217: 408-17.
53. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289:210-6.
54. Nordberg A, Alafuzoff I, Winbald B. Nicotinic and muscarinic receptor subtypes in the human brain: changes with aging and dementia. J Neurosci Res 1992;31:103-11.
55. Warpman U, Alafuzoff I, Nordberg A. Coupling of muscarinic receptors to GTP proteins in postmortem human brain - alterations in Alzheimer's disease. Neurosci Lett 1993;150:39-43.
56. Rodriguez-Puertas R, Pascual J, Vilaro T, Pazos A. Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease. Synapse 1997;26:341-50.
57. Mulugeta E, Karlsson E, Islam A, Kalaria R, Mangat H, Winblad B, et al. Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients. Brain Res 2003;960:259-62.
58. McGehee OS, Role LW. Physiological diversity of nicotine acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 1995;57:521-46.
59. Colquhoun LM, Patrick JW. Pharmacology of neuronal nicotinic acetylcholine receptor subtypes. Adv Pharmacol 1997;39: 191-20.
60. 7 subunit homomers. J Neurosci 2000;20:133-9.
61. 11C-nicotine binding in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 1995;9:21-7.
62. Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E. Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 2001;49:175-84.
63. 7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia 2003;41:207-11.
64. Kang J, Lemaire GH, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell surface receptor. Nature 1987;325:733-6.
65. Koo EH, Sisodia SS, Cork LC, Unterbeck A, Bayney RM, Price DL. Differential expression of amyloid precursor protein mRNAs in cases of Alzheimer's disease and in aged nonhuman primates. Neuron 1990;4(1):97-104.
66. Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, Rulicke T. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci 2000;20:7951-63.
67. Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, et al. Cleavage of amyloid β-peptide during constitutive processing of its precursor. Science 1990;248:1122-4.
68. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286:735-41.
69. Kimberly WT, La Voie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci USA 2003;100:6382-7.
70. Haass C, Steiner H. Alzheimer disease γ-secretase: a complex story of GxGD-type presenilin proteases. Trends Cell Biol 2002; 12:556-62.
71. Roberson MR, Harrell LE. Cholinergic and amyloid precursor protein metabolism. Brain Res Rev 1997;25:50-69.
72. Mills J, Reiner PB. Regulation of amyloid precursor protein cleavage. J Neurochem 1999;72:443-60.
73. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic cholinergic receptor. Science 1992;258:304-7.
74. Pittel Z, Heldman E, Barg J, Haring R, Fisher A. Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum. Brain Res 1996;742:299-304.
75. Hellstrom-Lindahl E. Modulation of β-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors. Eur J Pharmacol 2000;393:255-63.
76. Kim SH, Kim YK, Jeong SJ, Haass C, Kim YH, Suh YH. Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine. Mol Pharmacol 1997;52:430-6.
77. Lahiri DK, Utsuki T, Chen D, Farlow MR, Shoaib M, Ingram DK, et al. Nicotine reduces the secretion of Alzheimer's β-amyloid precursor protein containing β-amyloid peptide in the rat without altering synaptic proteins. Ann N Y Acad Sci 2002;965:364-72.
78. Buxbaum JD, Ruefli AA, Parker CA, Cypress AA, Greengard P. Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc Natl Acad Sci USA 1994;91:4489-93.
79. Lahiri DK, Farlow MR, Hintz N, Utsuki T, Greig NH. Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease. Acta Neurol Scand Suppl 2000;176:60-7.
80. Racchi M, Sironi M, Caprera A, Konig G, Govoni S. Short- and long-term effect of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein. Mol Psychiatry 2001;6:520-8.
81. Racchi M, Govoni S. The pharmacology of amyloid precursor protein processing. Exp Gerontology 2003;38:145-57.
82. Mori F, Lai CC, Fusi F, Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuro Report 1995;6:633-6.
83. Shaw KT, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A, et al. Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 2001;98:7605-10.
84. Kar S, Issa AM, Seto D, Auld DS, Collier B, Quirion R. Amyloid β-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J Neurochem 1998; 70:2179-87.
85. Kristofikova Z, Tekalova H, Klaschka J. Amyloid beta peptide 1-40 and the function of rat hippocampal hemicholinium-3 sensitive choline carriers: effects of a proteolytic degradation in vitro. Neurochem Res 2001;26:203-12.
86. Kar S, Seto D, Gaudreau P, Quirion R. β-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal formation. J Neurosci 1996;16:1034-40.
87. 1 protein. Neuropeptides 1999;33:197-205.
88. Melo JB, Agostinho P, Oliveira CR. Amyloid beta-peptide 25-35 reduces [3H]acetylcholine release in retinal neurons. Involvement of metabolic dysfunction. Amyloid 2002;9:221-8.
89. Satoh Y, Hirakura Y, Shibayama S, Hirashima N, Suzuki T, Kirino Y. Beta-amyloid peptides inhibit acetylcholine release from cholinergic nerve endings isolated from an electric ray. Neurosci Lett 2001;302:97-100.
90. Vaucher E, Aumont N, Pearson D, Rowe W, Poirier J, Kar S. Amyloid β peptide levels and its effects on hippocampal acetylcholine release in aged, cognitively-impaired and -unimpaired rats. J Chem Neuroanat 2001;21:323-9.
91. Lee TF, Shiao YJ, Chen CF, Wang LC. Effect of ginseng saponins on beta-amyloid-suppressed acetylcholine release from rat hippocampal slices. Planta Med 2001;67:634-7.
92. Jhamandas JH, Cho C, Jassar B, Harris K, MacTavish D, Easaw J. Cellular mechanisms for amyloid β-protein activation of rat basal forebrain neurons. J Neurophysiol 2001;86:1312-20.
93. 1-42 supresses acetylcholine synthesis. J Biol Chem 1997;272:2038-41.
94. Pedersen WA, Kloczewiak MA, Blusztajn JK. Amyloid β-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurones of the basal forebrain. Proc Natl Acad Sci USA 1996;93:8068-71.
95. Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S. Amyloid β peptide induces tau phosphorylation and neuronal degeneration in rat primary septal cultured neurons. Neuroscience 2002;115:201-11.
96. Pedersen WA, Blusztajn JK. Characterization of the acetylcholine reducing effect of the amyloid-beta peptide in mouse SN56 cells. Neurosci Lett 1997;239:77-80.
97. Kelly JF, Furukawa K, Barger SW, Rengen MR, Mark RJ, Blanc EM, et al. Amyloid β-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc Natl Acad Sci USA 1996;93:6753-8.
98. Le W, Xie WJ, Kong R, Appel SH. β-amyloid-induced neurotoxicity of a hybrid septal cell line associated with increased tau phosphorylation and expression of β-amyloid precursor protein. J Neurochem 1997;69:978-85.
99. Olesen OF, Dago L, Mikkelsen JD. Amyloid β neurotoxicity in the cholinergic but not in the serotonergic phenotype of RN46A cells. Mol Brain Res 1998;57:266-74.
100. Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002;68:209-45.
101. Dolezal V, Kasparova J. β-amyloid and cholinergic neurons. Neurochem Res 2003;28:499-506.
102. Kar S. Role of amyloid β peptides in the regulation of central cholinergic function and its relevance to Alzheimer's disease pathology. Drug Res Dev 2002;56:248-63.
103. Wecker L. The synthesis and release of acetylcholine by depolarized hippocampal slices is increased by increased choline available in vitro prior to stimulation. J Neurochem 1991;57: 1119-27.
104. Zambrzycka A, Alberghina M, Strosznajder JB. Effects of aging and amyloid-beta peptides on choline acetyltransferase activity in rat brain. Neurochem Res 2002;27:277-81.
105. Dobransky T, Brewer D, Lajoie G, Rylett RJ. Phosphorylation of 69-kDa choline acetyltransferase at threonine 456 in response to amyloid-beta peptide 1-42. J Biol Chem 2003;278: 5883-93.
106. Joslin G, Krause JE, Hershey AD, Adams SP, Fallen RJ, Perimutter DH. Amyloid-β peptide, substance P, and bombesin bind to the serpin-enzyme complex receptor. J Biol Chem 1991;266:21897-902.
107. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD. Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils. Nature 1996;382:716-9.
108. Van SD, Chen X, Fu J, Chen M, Zhu H, Roher A. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-91.
109. NTR and activates NFkB in human neuroblastoma cells. J Neurosci Res 1998;54:798-804.
110. 7 nicotinic acetylcholine receptors. J Neurochem 2000;75:1155-61.
111. 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA 2001;98:4734-9.
112. 1-42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 2001;21:RC120-24.
113. 1-42. J Neurobiol 2003;55:25-30.
114. Jhamandas JH, Harris KH, Cho C, Fu W, MacTavish D. Human amylin actions on rat cholinergic basal forebrain neurons: antagonism of beta-amyloid effects. J Neurophysiol 2003;89(6): 2923-30.
115. Huang HM, Ou HC, Hsieh SJ. Amyloid beta peptide impaired carbachol but not glutamate-mediated phosphoinositide pathways in cultured rat cortical neurons. Neurochem Res 2000;25: 303-12.
116. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545-84.
117. Pike CJ, Cotman CW. Cultured GABA-immunoreactive neurons are resistant to toxicity induced by β-amyloid. Neuroscience 1993;56:269-74.
118. Behl C, Cole GM, Schubert D. Vitamin E protects nerve cells from amyloid β protein toxicity. Biochem Biophys Res Commun 1992;186:944-50.
119. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. β-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992;12:376-89.
120. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, et al. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 1994;91: 3270-4.
121. Perini G, Della-Bianca V, Politi V, Della Valle G, Dal-Pra I, Rossi F, et al. Role of p75 neurotrophin receptor in the neurotoxicity by beta-amyloid peptides and synergistic effect of inflammatory cytokines [published erratum appears in J Exp Med 2002;195(9):1231]. J Exp Med 2002;195:907-18
122. Perini G, Della-Bianca V, Politi V, Della Valle G, Dal-Pra I, Rossi F, et al. Role of p75 neurotrophin receptor in the neurotoxicity by beta-amyloid peptides and synergistic effect of inflammatory cytokines [published erratum appears in J Exp Med 2002;195(9):1231]. J Exp Med 2002;195:907-18
123. Nagele RG, D'Andrea MR, Anderson WJ, Wang HY. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 2002;110:199-211.
124. Allen DD, Galdzicki Z, Brining SK, Fukuyama R, Rapoport SI, Smith QR. Beta-amyloid induced increase in choline flux across PC12 cell membranes. Neurosci Lett 1997;234:71-3.
125. Wurtman R. Choline metabolism as a basis for the selective vulnerability of cholinergic neurones. Trends Neurosci 1992;15: 117-22.
126. Busciglio J, Lorenzo A, Yeh J, Yankner BA. β-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995;14:879-88.
127. Shea TB, Prabhakar S, Ekinci FJ. β-amyloid and ionophore A23187 evoke tau hyper-phosphorylation by distinct intracellular pathways: differential involvement of the calpain/ protein kinase C system. J Neurosci Res 1997;49:759-68.
128. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. Lithium protects cultured neurons against β-amyloid-induced neurodegeneration. FEBS Lett 1999;453:260-4.
129. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide. J Neurochem 1997;68:255-64.
130. Greenberg SM, Kosik KS. Secreted β-APP stimulates MAP kinase and phosphorylation of tau in neurons. Neurobiol Aging 1995;16:403-8.
131. Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, et al. Activation of tau protein kinase I/ glycogen synthase kinase-3 beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res 1998;4:317-23.
132. Alvarez A, Toro R, Caceres A, Maccioni RB. Inhibition of tau phosphorylating protein kinase cdk5 prevents β-amyloid-induced neuronal death. FEBS Lett 2001;459:421-6.
133. Hong M, Chen DCR, Klein PS, Lee VMY. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 1997;40:25326-32.
134. Sadot E, Gurwitz D, Barg J, Behar L, Ginzburg I, Fisher A. Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J Neurochem 1996;66:877-80.
135. Hellstrom-Lindahl E, Moore H, Nordberg A. Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J Neurochem 2000;74:777-84.
136. Abe E, Casamenti F, Giovannelli L, Scali C, Pepeu G. Administration of amyloid β-peptides into the medial septum of rats decreases acetylcholine release from hippocampus in vivo. Brain Res 1994;636:162-4.
137. Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, et al. Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis 2002;11:257-74.
138. Boncristiano S, Calhoun ME, Kelly PH, Pfeifer M, Bondolfi L, Stalder M, et al. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci 2002;22:3234-43.
139. Bronfman FC, Moechars D, Van Leuven F. Acetyl-cholinesterase-positive fiber deafferentation and cell shrinkage in the septohippocampal pathway of aged amyloid precursor protein london mutant transgenic mice. Neurobiol Dis 2000;7: 152-68.
140. Wong TP, Debeir T, Duff K, Cuello AC. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J Neurosci 1999;19:2706-16.
141. 75NTR cholinergic basal forebrain septohippocampal pathway. Exp Neurol 2001;170: 227-43.
142. Gau JT, Steinhilb ML, Kao TC, D'Amato CJ, Gaut JR, Frey KA, et al. Stable β-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. Am J Pathol 2002;160:731-8.
143. Vaucher E, Fluit P, Chishti MA, Westaway D, Mount HTJ, Kar S. Alteration in working memory but not cholinergic receptor binding sites in transgenic mice expressing human presenilin 1 transgenes. Exp Neurol 2002;21:323-9.
144. 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem 2002;227:22768-80.
145. Chishti MA, Yang DS, Janus C, Phinney AL, Home P, Pearson J, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001;276:21562-70.
146. Slowikowski SPM, Chishti MA, Zheng WH, Mount HTJ, Westaway D, Kar S. Alterations in cholinergic parameters in the hippocampus of transgenic mice expressing mutated amyloid precursor protein and/or presenilin-1 transgenes (poster). Program no. 295.18. 2002 Abstract Viewer/Itinerary Planner. Washington: Society for Neuroscience; 2002. Available: http://sfn.scholarone. com/itin2002/index.html (accessed 2004 Oct 15).
147. Apelt J, Kumar A, Schliebs R. Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human beta-amyloid precursor protein. Brain Res 2002;953:17-30.
148. Iverfeldt K, Walaas SI, Greengard P. Altered processing of Alzheimer amyloid precursor protein in response to neuronal degeneration. Proc Natl Acad Sci USA 1993;90:4146-50.
149. Wallace W, Ahlers ST, Gotlib J, Bragin V, Sugar J, Gluck R, et al. Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. Proc Natl Acad Sci USA 1993;90:8712-6.
150. Lin L, Georgievska B, Mattsson A, Isacson O. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc Natl Acad Sci USA 1999;96:12108-13.
151. 4 amyloid precursor protein. Proc Natl Acad Sci USA 1992;89:10075-8.